Marsh & McLennan Companies: A Global Leader in Professional Services

Marsh & McLennan Companies, Inc. (MRSH) is a global professional services and risk advisory firm with a market capitalization of $89.6 billion. The New York-based company operates through two key segments: Risk and Insurance Services and Consulting, serving a diverse range of clients worldwide.

Performance of MRSH Stock

Over the past 52 weeks, MRSH stock has struggled to keep pace with the broader market. The company’s shares have decreased by 9.3%, while the S&P 500 Index has rallied by 20.4%. On a year-to-date basis, shares of MRSH are up 1.2%, compared to the SPX’s 13.7% gain.

In addition, MRSH shares have underperformed the State Street Financial Select Sector SPDR ETF (XLF) by 9.7% over the past 52 weeks and 6.2% in 2026.

Recent Earnings Release and Market Reaction

On July 21, Marsh & McLennan released its FY2026 Q2 earnings, which led to a 3.1% dip in its shares in the next trading session. The weakness in the company’s Guy Carpenter segment, continued reinsurance pricing pressure, and a relatively modest beat against elevated expectations contributed to this decline.

Despite this, the company’s consolidated revenue increased by 6.2% year over year to approximately $7.40 billion, while underlying revenue growth was 5%. Adjusted operating income rose by 5.3% year over year to $2.17 billion, reflecting continued operating leverage. The company’s adjusted earnings per share (EPS) climbed by 8.8% to $2.96, beating consensus estimates of around $2.90.

Analyst Expectations and Consensus Rating

For the fiscal year ending in December 2026, analysts expect Marsh & McLennan’s adjusted EPS to grow by 7% year over year to $10.43. The company’s earnings surprise history is promising, having beaten consensus estimates in the last four quarters.

A total of 25 analysts cover MRSH stock, with a consensus rating of ‘Moderate Buy.’ This is based on seven ‘Strong Buy’ ratings, 17 ‘Hold’ ratings, and one ‘Moderate Sell’ rating.

Price Target and Potential Upside

UBS analyst Brian Meredith recently reiterated a ‘Buy’ rating on MRSH and raised his price target to $216 from $212. The mean price target of $202.54 represents a 7.8% premium to MRSH’s current price levels. The Street-high price target of $234 suggests a 24.6% potential upside.

The company’s shares have a promising earnings surprise history, and analysts remain optimistic about its future performance.